107 related articles for article (PubMed ID: 23114131)
21. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Österborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Clin Cancer Res; 2012 Apr; 18(8):2230-9. PubMed ID: 22392915
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
23. Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
Ouyang GF; Lin MF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1468-71. PubMed ID: 20030928
[TBL] [Abstract][Full Text] [Related]
24. [Effect of bortezomib and arabinoside on proliferation and apoptosis of K562 cell.].
Lu SF; Lu Q
Zhonghua Xue Ye Xue Za Zhi; 2010 Jan; 31(1):42-5. PubMed ID: 20302779
[TBL] [Abstract][Full Text] [Related]
25. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
27. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Zhou RQ; Gong YP; Zheng BH; Yang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):789-92. PubMed ID: 21302442
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
30. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
31. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Schmitt S; Ho AD; Goldschmidt H
Onkologie; 2010; 33(4):183-6. PubMed ID: 20389145
[TBL] [Abstract][Full Text] [Related]
32. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
[TBL] [Abstract][Full Text] [Related]
33. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
34. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
35. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
36. [Anti-proliferation Effect of NS-398 in Combination with Bortezomib on Multiple Myeloma RPMI 8226 Cells In Vitro].
Que WZ; Chen JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1426-1430. PubMed ID: 29070119
[TBL] [Abstract][Full Text] [Related]
37. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
[TBL] [Abstract][Full Text] [Related]
38. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
[TBL] [Abstract][Full Text] [Related]
39. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
40. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]